Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 30, 2026, 6:00 AM ET
IDEAYA Biosciences announced that on October 29, 2026, its Compensation Committee granted non-qualified stock options for an aggregate of 99,600 shares to four newly hired employees under the 2023 Inducement Plan, with an exercise price of $32.89 per share.
$IDYABiotechnologyClinical evidenceDevelopment risk
IDYA Stock Hub: IDEAYA Biosciences News, Darovasertib and Precision Oncology
IDEAYA is advancing darovasertib across distinct uveal-melanoma settings and developing a broader precision-oncology pipeline. The ESMO presentations are past; OptimUM-11 has begun dosing. June cash and securities of approximately $1.24 billion fund a growing development program, without removing efficacy or dilution risk.
Full research report · PDF
IDEAYA Biosciences ($IDYA), archive captured October 31, 2026
17 pages covering Archived research separates metastatic, neoadjuvant and adjuvant darovasertib programs and examines the evidence behind the wider precision-oncology pipeline. It covers IDE849 trial design and early data, synthetic-lethality programs, partner rights, June resources, rising research spending and equity compensation. The original research revision date is not stated; the date above records when this archive copy was captured. The hub follows later developments. For personal use only: redistribution prohibited.
Next announced investor event
November 16, 2026
London Investor R&D Day at 5:00 p.m. GMT, focused on pancreatic-cancer strategy and preclinical data.
ESMO October 23–27 is past. The investor event is separate from pivotal results, an accepted NDA or an FDA decision.
IDYA stock at a glance
Close · October 30, 2026
$31.96
Regular-session close; -2.83% versus $32.89 on October 29, 2026.
Cash + marketable securities · June 30, 2026
~$1.24B
The company states these resources will fund planned operations for at least twelve months from the date the quarterly report was issued. Company filing
Operating cash use · H1 2026
$163.4M
Net cash used in operating activities, six months to June 30; $122.8M a year earlier. The spending is rising as the programmes move into late-stage trials. Company filing
Research and development · Q2 2026
$108.7M
$74.2M in the same quarter of 2025, and $204.4M over the first half against $145.1M. Company filing
Net loss · Q2 2026
$112.5M
$(1.22) per share, against $77.5M and $(0.88) a year earlier; $211.0M and $(2.33) over the first half. Company filing
Collaboration revenue · Q2 2026
$8.9M
Against nothing in the same quarter of 2025; $15.4M over the first half. This is collaboration income rather than product sales; the company also reported collaboration revenue in earlier years. Company filing
Shares outstanding · July 31, 2026
96,489,484
Cover of the Q2 2026 Form 10-Q. Free float 90.08 million shares, as of October 2, 2026. Company filing
Equity value · dated shares
~$3.08B
Calculated using October 30 close and 96,489,484 common shares at July 31, 2026; later changes excluded.
Where IDEAYA Biosciences stands now
The strongest version of the IDYA thesis is not “one good biotech result.” It is that darovasertib has generated randomized registrational evidence in a biologically defined cancer with major unmet need, while IDEAYA has accumulated enough capital to build the U.S. commercial infrastructure and continue funding multiple independent oncology platforms.
Separate indications have separate evidence and regulatory paths. Metastatic, neoadjuvant and adjuvant uveal-melanoma studies are not interchangeable. Early IDE849 observations require confirmation; collaboration revenue is not commercial product revenue.
The constructive case
Within twelve days the company moved three separate programmes forward on paper: a regulatory path for IDE849 discussed with the FDA in a proposed design intended to support potential accelerated and full approval, a second Roche-group partner willing to sponsor a combination trial for IDE892 , and a dated venue in November to lay out the MTAP/CDKN2A and KRAS strategy. The DLL3 population IDEAYA is aiming at is not small on its own estimates: roughly 34,000 SCLC and 19,000 NEC patients a year in the United States. The institutional ownership field of 101.91% reflects overlapping or differently dated reports; it cannot measure incremental investor conviction.
The cautious case
None of the three announcements is data. FDA feedback from a Type C meeting is preliminary and nonbinding , and the agency can still require changes to the design, the endpoints or the population; the company says so itself. The Phase 3 has not started, the recommended Phase 3 dose is not yet chosen between 2.4 and 3.5 mg/kg, and the London event promises preclinical data. Short interest at 11.03% (as of October 2, 2026) of the float is not a small position against a company whose value still rests on outcomes that have not been read out.
Latest IDEAYA Biosciences news
October 30, 2026
Inducement options granted to four new employees
The company announced 99,600 options granted October 29 at $32.89 per share to four new employees. The awards have a 10-year term and four-year service-based vesting; grants are neither immediate issued shares nor financing proceeds.
October 23, 2026
Updated IDE849 Phase 1 evidence at ESMO
Updated partner-reported Phase 1 data included median overall survival of 17.4 months in 51 second-line SCLC patients. The uncontrolled early study in China does not establish superiority over another treatment or a registrational outcome.
October 19, 2026
Updated darovasertib data from three studies released ahead of ESMO
IDEAYA and Servier released updated data from OptimUM-01, OptimUM-02 and OptimUM-09, to be presented in poster sessions at ESMO on October 24, 12:00–12:45 p.m. CEST (the congress runs October 23–27). In OptimUM-01 (single-arm Phase 2 expansion, HLA-A*02:01-positive metastatic uveal melanoma, March 23, 2026 cutoff, 101 patients, median follow-up 10.4 months) the efficacy-evaluable population showed an objective response rate of 22.1% (19/86), disease control of 80.2%, median duration of response of 7.4 months, median PFS of 5.4 months and median overall survival of 13.4 months. In the 13 treatment-naive patients median PFS was 7.4 months and median overall survival 27.1 months (response rate 36.4%, 4/11); in the 15 patients previously treated only with tebentafusp, median PFS was 5.7 months and median overall survival 12.1 months. About 66% of all patients had received two or more prior lines. The most common treatment-related adverse events were diarrhea (82%), nausea (76%), peripheral edema (70%) and vomiting (57%), and 8.9% discontinued because of related events. For OptimUM-02, the randomized first-line HLA-A*02:01-negative trial, the company reported consistent improvements in response rate and PFS versus investigator’s choice across subgroups defined by LDH, ECOG status, lesion size and control therapy, with worse outcomes at higher tumor burden. OptimUM-09, the neoadjuvant study in primary disease, continued to show tumor shrinkage in more than 80% of patients, a 57% eye-preservation rate in the enucleation cohort and a reduced projected radiation dose in 66% of the plaque brachytherapy cohort (116 patients in the abstract, 119 in the updated analysis). Single-arm cohorts with small treatment-naive denominators, and comparisons with historical benchmarks, are not a randomized comparison.
October 6, 2026
CEO files proposed option-share sale
The chief executive officer filed a Form 144 for the proposed sale of 230,316 shares acquired through an option exercise, under a Rule 10b5-1 plan adopted July 7, 2026. The notice reports an aggregate market value of about $8.80 million. This is a notice of intent, not a confirmed sale or company financing.
September 28, 2026
Chief scientific officer promoted to President, Research and Development
On September 28, IDEAYA promoted its Chief Scientific Officer to President, Research and Development, effective the same day. The executive had served as CSO since 2021. This is a leadership update, not a clinical readout or regulatory decision.
September 9, 2026
OptimUM-11 first patient dosed
The Phase 3 adjuvant darovasertib-plus-crizotinib trial began dosing after local therapy in primary uveal melanoma at elevated metastatic risk. Study initiation does not report efficacy.
IDYA stock catalysts: development and reporting dates
- November 16, 2026 — London R&D Day,5:00 p.m. GMT. Company-announced investor event
- Year-end 2026 — Targeted IDE849 registrational study initiation. Company development target
October 30 employee awards · London investor R&D Day announcement · Current primary newsroom
Darovasertib across distinct uveal-melanoma settings
Darovasertib is an oral inhibitor of protein kinase C, or PKC. Uveal melanoma is molecularly distinct from cutaneous melanoma. Activating changes in GNAQ or GNA11 are common drivers, and PKC sits downstream in the signaling pathway. The therapeutic thesis is that suppressing PKC attacks a central oncogenic dependency. Crizotinib inhibits c-MET, a pathway implicated in resistance and adaptive signaling, so the combination is designed to produce a more complete and durable block than darovasertib alone.
The first filing population may be only the beginning. The long-term franchise thesis rests on three expansion vectors: HLA-positive metastatic disease, neoadjuvant treatment before local therapy and adjuvant treatment to prevent relapse.
IDEAYA pipeline and capital requirements
At June 30, 2026, IDEAYA held approximately $1.24 billion in cash, cash equivalents and marketable securities, up from $972.9 million at March 31 after the June offering and the at-the-market programme. Q2 collaboration revenue was $8.9 million, research and development expense was $108.7 million, general and administrative expense was $22.5 million and net loss was $112.5 million, or $1.22 per share. For the first half, revenue was $15.4 million, the net loss was $211.0 million and net cash used in operations was $163.4 million. Net cash used in operations is the cleaner runway input than net loss because stock compensation and working-capital movements affect the accounting result. Management had guided that the balance sheet could fund operations into 2030 before the June equity raise. The June transaction therefore looks like opportunistic financing after clinical de-risking rather than emergency financing. That is positive for program continuity. It is not free capital.
Merlintrader Health Score · $IDYA
3.80out of 5
Assessed October 4, 2026. Weighted calculation: 4.5×30% + 3.5×30% + 3.5×20% + 4.0×10% + 3.0×10% = 3.80. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Metastatic, neoadjuvant and adjuvant uveal-melanoma studies are not interchangeable. Early IDE849 observations require confirmation; collaboration revenue is not commercial product revenue.
- None of the three announcements is data. FDA feedback from a Type C meeting is preliminary and nonbinding , and the agency can still require changes to the design, the endpoints or the population; the company says so itself. The Phase 3 has not started, the recommended Phase 3 dose is not yet chosen between 2.4 and 3.5 mg/kg, and the London event promises preclinical data. Short interest at 11.03% (as of October 2, 2026) of the float is not a small position against a company whose value still rests on outcomes that have not been read out.
IDYA Stock FAQ: IDEAYA Biosciences Questions Answered
How much cash does IDEAYA have?
About $1.24 billion of cash, cash equivalents and marketable securities at June 30, 2026. The company states in its Form 10-Q that these resources will fund planned operations for at least twelve months from the date the report was issued. Operating activities used $163.4 million in the first half, against $122.8 million a year earlier.
Does IDEAYA have any revenue?
It reported collaboration revenue of $8.9 million in the second quarter of 2026 and $15.4 million over the first half, against nothing in the same periods of 2025. That is partnership income, not product sales: the company has no approved product.
How large is the loss?
A net loss of $112.5 million in the second quarter of 2026, $(1.22) per share, against $77.5 million and $(0.88) a year earlier, and $211.0 million over the first half at $(2.33) per share. Research and development rose to $108.7 million in the quarter from $74.2 million, which is where the increase comes from.
What is darovasertib?
IDEAYA’s lead clinical asset, in uveal melanoma. It is the programme closest to a regulatory filing and the reason the rest of the pipeline is being funded. It remains investigational: nothing on this page describes an approved medicine.
Is this page a recommendation to buy or sell $IDYA?
No. This Stock Hub is informational and educational. It sets out dated facts, their sources and the scenarios they leave open. It does not recommend any action.
Primary sources
- October 30, 2026 · Inducement options granted to four new employees
- October 23, 2026 · Updated IDE849 Phase 1 evidence at ESMO
- October 19, 2026 · Updated darovasertib data from three studies released ahead of ESMO
- October 6, 2026 · CEO files proposed option-share sale
- September 28, 2026 · Chief scientific officer promoted to President, Research and Development
- September 9, 2026 · OptimUM-11 first patient dosed
- London investor R&D Day announcement
- Current primary newsroom
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $IDYA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
